{"filing":{"accession_number":"0001104659-26-090704","cik":"0001651625","ticker":"ACIU","company_name":"AC Immune SA","form":"6-K","filing_date":"2026-08-05","report_date":"2026-06-30","primary_document":"aciu-20260630x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651625/000110465926090704/aciu-20260630x6k.htm"},"events":[{"id":24383,"run_id":22089,"accession_number":"0001104659-26-090704","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"AC Immune disclosed first-half 2026 financial results with revenue of CHF 16.2 million, R\u0026D expenses of CHF 22.2 million, and a net loss of CHF 12.9 million for the six months ended June 30, 2026, accompanied by condensed consolidated financial statements.","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-05","form":"6-K","submitted_at":null,"items":[{"id":24917,"accession_number":"0001104659-26-090704","item_number":"EX-99.3","item_title":"aciu-20260630xex99d3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing AC Immune's first-half 2026 financial and corporate results, including revenue of CHF 16.2 million, R\u0026D expenses of CHF 22.2 million, and a net loss of CHF 12.9 million for the six months ended June 30, 2026. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, and comprehensive income statement) and is titled \"AC Immune First Half 2026 Financial and Corporate Update.\" This is a periodic interim financial results announcement, classified as an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:31:10.360694+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":24384,"run_id":22089,"accession_number":"0001104659-26-090704","anchor_item_number":"EX-99.4","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"summary":"AC Immune furnished its Articles of Association containing standard corporate governance provisions regarding share capital structure, conditional capital, and share transfer restrictions.","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-05","form":"6-K","submitted_at":null,"items":[{"id":24918,"accession_number":"0001104659-26-090704","item_number":"EX-99.4","item_title":"aciu-20260630xex99d4.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit is the Articles of Association (bylaws) of AC Immune SA, a Swiss pharmaceutical company. It contains standard corporate governance provisions regarding share capital structure, capital bands, conditional capital for financing and employee benefit plans, and share transfer restrictions. While bylaws amendments can be material when they substantively alter shareholder rights or governance, this appears to be a routine filing of the company's governing documents—likely furnished as part of a periodic disclosure or corporate housekeeping. The content is administrative and procedural rather than announcing a discrete governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:31:10.360694+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24915,"accession_number":"0001104659-26-090704","item_number":"EX-99.1","item_title":"aciu-20260630xex99d1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an interim condensed consolidated financial statement for AC Immune SA covering the six months ended June 30, 2026. It includes balance sheets, statements of income/loss, comprehensive income/loss, changes in equity, and cash flows — the standard components of an interim financial report. The document is explicitly labeled as \"Interim Condensed Consolidated Financial Statements (Unaudited)\" and covers a six-month period, making it a periodic interim report rather than a discrete event disclosure. Routine interim financial statements are not material events in the sense of 8-K/6-K Item classification; they are periodic filings deferred for separate processing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:31:10.360694+00:00","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-05"},{"id":24916,"accession_number":"0001104659-26-090704","item_number":"EX-99.2","item_title":"aciu-20260630xex99d2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) accompanying unaudited interim condensed consolidated financial statements for the six months ended June 30, 2026, as explicitly stated in the opening paragraph. It is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event disclosure. The MD\u0026A itself is a required component of the periodic report and should be deferred for separate processing as `periodic_interim`.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:31:10.360694+00:00","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-05"},{"id":24917,"accession_number":"0001104659-26-090704","item_number":"EX-99.3","item_title":"aciu-20260630xex99d3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing AC Immune's first-half 2026 financial and corporate results, including revenue of CHF 16.2 million, R\u0026D expenses of CHF 22.2 million, and a net loss of CHF 12.9 million for the six months ended June 30, 2026. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, and comprehensive income statement) and is titled \"AC Immune First Half 2026 Financial and Corporate Update.\" This is a periodic interim financial results announcement, classified as an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:31:10.360694+00:00","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-05"},{"id":24918,"accession_number":"0001104659-26-090704","item_number":"EX-99.4","item_title":"aciu-20260630xex99d4.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit is the Articles of Association (bylaws) of AC Immune SA, a Swiss pharmaceutical company. It contains standard corporate governance provisions regarding share capital structure, capital bands, conditional capital for financing and employee benefit plans, and share transfer restrictions. While bylaws amendments can be material when they substantively alter shareholder rights or governance, this appears to be a routine filing of the company's governing documents—likely furnished as part of a periodic disclosure or corporate housekeeping. The content is administrative and procedural rather than announcing a discrete governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:31:10.360694+00:00","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-05"}]}